This company has been marked as potentially delisted and may not be actively trading. Gemphire Therapeutics (GEMP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock GEMP vs. KRON, RANI, SPRO, ITRM, LTRN, ELYM, ACRV, ONCY, ATHE, and RMTIShould you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include Kronos Bio (KRON), Rani Therapeutics (RANI), Spero Therapeutics (SPRO), Iterum Therapeutics (ITRM), Lantern Pharma (LTRN), Eliem Therapeutics (ELYM), Acrivon Therapeutics (ACRV), Oncolytics Biotech (ONCY), Alterity Therapeutics (ATHE), and Rockwell Medical (RMTI). These companies are all part of the "medical" sector. Gemphire Therapeutics vs. Kronos Bio Rani Therapeutics Spero Therapeutics Iterum Therapeutics Lantern Pharma Eliem Therapeutics Acrivon Therapeutics Oncolytics Biotech Alterity Therapeutics Rockwell Medical Gemphire Therapeutics (NASDAQ:GEMP) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment. Does the media favor GEMP or KRON? In the previous week, Gemphire Therapeutics' average media sentiment score of 0.00 equaled Kronos Bio'saverage media sentiment score. Company Overall Sentiment Gemphire Therapeutics Neutral Kronos Bio Neutral Do insiders and institutionals believe in GEMP or KRON? 17.5% of Gemphire Therapeutics shares are owned by institutional investors. Comparatively, 64.1% of Kronos Bio shares are owned by institutional investors. 22.7% of Gemphire Therapeutics shares are owned by insiders. Comparatively, 24.4% of Kronos Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is GEMP or KRON more profitable? Gemphire Therapeutics has a net margin of 0.00% compared to Kronos Bio's net margin of -867.66%. Kronos Bio's return on equity of -64.55% beat Gemphire Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemphire TherapeuticsN/A -419.70% -173.05% Kronos Bio -867.66%-64.55%-48.18% Do analysts rate GEMP or KRON? Kronos Bio has a consensus price target of $1.63, suggesting a potential upside of 135.95%. Given Kronos Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kronos Bio is more favorable than Gemphire Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemphire Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kronos Bio 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more risk and volatility, GEMP or KRON? Gemphire Therapeutics has a beta of 2.82, indicating that its share price is 182% more volatile than the S&P 500. Comparatively, Kronos Bio has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Does the MarketBeat Community prefer GEMP or KRON? Gemphire Therapeutics received 268 more outperform votes than Kronos Bio when rated by MarketBeat users. Likewise, 69.98% of users gave Gemphire Therapeutics an outperform vote while only 65.63% of users gave Kronos Bio an outperform vote. CompanyUnderperformOutperformGemphire TherapeuticsOutperform Votes28969.98% Underperform Votes12430.02% Kronos BioOutperform Votes2165.63% Underperform Votes1134.38% Which has preferable earnings and valuation, GEMP or KRON? Gemphire Therapeutics has higher earnings, but lower revenue than Kronos Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemphire TherapeuticsN/AN/A-$23.64MN/AN/AKronos Bio$9.19M4.57-$112.67M-$1.07-0.64 SummaryKronos Bio beats Gemphire Therapeutics on 8 of the 13 factors compared between the two stocks. Get Gemphire Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEMP vs. The Competition Export to ExcelMetricGemphire TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.05M$6.48B$5.33B$8.31BDividend YieldN/A2.64%5.20%4.10%P/E RatioN/A8.4026.7219.60Price / SalesN/A258.84395.56117.96Price / CashN/A65.8538.3234.62Price / Book1.506.416.764.50Net Income-$23.64M$143.73M$3.23B$248.40M Gemphire Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GEMPGemphire TherapeuticsN/A$0.81-7.5%N/A-79.8%$12.05MN/A0.009Gap DownHigh Trading VolumeKRONKronos Bio2.4894 of 5 stars$0.69+2.7%$1.63+135.2%-31.2%$41.09M$9.19M-0.47100High Trading VolumeRANIRani Therapeutics2.2775 of 5 stars$0.72+2.1%$9.40+1,214.7%-87.6%$41.04M$1.03M-0.67110News CoverageAnalyst RevisionGap DownSPROSpero Therapeutics4.0903 of 5 stars$0.68-0.8%$5.00+631.0%-53.6%$38.24M$28.30M9.77150Gap DownITRMIterum Therapeutics1.8483 of 5 stars$0.94-5.5%$9.00+855.4%-34.4%$38MN/A-0.7310LTRNLantern Pharma3.0006 of 5 stars$3.51-2.2%$25.00+612.3%-48.1%$37.86MN/A-1.9720Analyst RevisionGap UpELYMEliem TherapeuticsN/A$1.27-1.6%N/A-84.6%$37.79MN/A-2.409News CoverageACRVAcrivon Therapeutics3.0217 of 5 stars$1.20+1.3%$17.71+1,382.4%-86.6%$37.47MN/A-0.4458ONCYOncolytics Biotech1.6367 of 5 stars$0.43-3.7%$4.33+912.5%-63.5%$37.08MN/A-1.5930Analyst ForecastAnalyst RevisionATHEAlterity Therapeutics1.9444 of 5 stars$4.17+3.1%$12.00+187.5%+109.5%$36.98MN/A0.0010Gap DownRMTIRockwell Medical4.0409 of 5 stars$1.08+3.4%$4.00+272.1%-44.9%$36.74M$97.73M-21.50300Analyst Revision Related Companies and Tools Related Companies Kronos Bio Competitors Rani Therapeutics Competitors Spero Therapeutics Competitors Iterum Therapeutics Competitors Lantern Pharma Competitors Eliem Therapeutics Competitors Acrivon Therapeutics Competitors Oncolytics Biotech Competitors Alterity Therapeutics Competitors Rockwell Medical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GEMP) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GEMP Stock Free GEMP Stock Alerts